Celltrion Expands U.S. Market Access for Omlyclo and Aptozma
Celltrion is expanding the U.S. commercial reach of its newer biosimilar products, securing exclusive supply agreements for Omlyclo and Aptozma that strengthen access to major healthcare networks, insurance coverage and retail pharmacy channels.The South Korean biopharmaceutical company said on Oct. 26 that its U.S. subsidiary had signed separate supply agreements for Omlyclo (omalizumab), a…
Celltrion, a South Korean biopharmaceutical company, has expanded its U.S. market access for two newer biosimilar products, Omlyclo and Aptozma, by securing exclusive supply agreements. These agreements are expected to strengthen access to major healthcare networks, insurance coverage, and retail pharmacy channels. The deals mark Celltrion's strategy to leverage relationships with insurers, healthcare providers, and pharmaceutical distributors to increase prescription volumes and sales of its newer, higher-margin products.
Brief written by urgent.news from Korea IT Times's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
